During an interview with Applied Clinical Trials editor Andy Studna at SCOPE, YPrime’s CEO, Jim Corrigan, elaborated on the Company’s initiatives to overcome challenges in clinical trials and provided insights from the company’s newly released eCOA report.
In this live video, YPrime CEO Jim Corrigan explains the company’s approach to addressing challenges in clinical trials, emphasizing their commitment to simplifying the process to benefit patients and sites. YPrime focuses on reducing delays, amendments, and dropouts by leveraging advanced technology and a modular system approach. This strategy enables faster start up and response to amendments, ensuring high-quality and timely data collection. Corrigan highlights the importance of making clinical trials less invasive and more accessible, aiming to match the right patient with the right outcome while maintaining compliance and safety.